Difficulty: Medium
Average Score: 62%
Practice
A 70-year-old man presents to clinic because of low-grade fever for the past 2 weeks. He otherwise feels well. On exam, the physician is able to palpate an enlarged spleen. A complete blood count shows a WBC count of 43,000/μL. A peripheral blood smear confirms the diagnosis of chronic myelogenous leukemia. Chromosomal studies are positive for the Philadelphia chromosome. What is the mechanism of action of the medication given to halt the progression of the disease?
Correct answer
D
Rationale
The correct answer is D) Tyrosine kinase inhibitor. In the context of chronic myelogenous leukemia (CML) with the Philadelphia chromosome, the primary driver mutation is the BCR-ABL fusion gene, which leads to constitutive activation of tyrosine kinase. Tyrosine kinase inhibitors, such as imatinib, are specifically designed to target and inhibit this aberrant kinase activity, thereby halting the progression of the disease.
Option A) Binds to CD20 antigen is incorrect because CD20 is a target for drugs like rituximab used in B-cell lymphomas, not in CML.
Option B) Binds to HER-2 is incorrect because HER-2 is a target in breast cancer, not in CML.
Option C) Cross-link DNA is incorrect because drugs that act by cross-linking DNA are typically used in conditions like lymphoma, not in CML.
Educationally, understanding the mechanism of action of medications in the context of specific diseases is crucial for effective patient management. Knowing the targeted therapy for CML helps healthcare providers make informed decisions about treatment options and improves patient outcomes by targeting the underlying molecular abnormalities driving the disease.
Option A) Binds to CD20 antigen is incorrect because CD20 is a target for drugs like rituximab used in B-cell lymphomas, not in CML.
Option B) Binds to HER-2 is incorrect because HER-2 is a target in breast cancer, not in CML.
Option C) Cross-link DNA is incorrect because drugs that act by cross-linking DNA are typically used in conditions like lymphoma, not in CML.
Educationally, understanding the mechanism of action of medications in the context of specific diseases is crucial for effective patient management. Knowing the targeted therapy for CML helps healthcare providers make informed decisions about treatment options and improves patient outcomes by targeting the underlying molecular abnormalities driving the disease.